📊 RGEN Key Takeaways
Is Repligen Corp. (RGEN) a Good Investment?
Repligen demonstrates strong financial health with excellent liquidity, conservative leverage, and robust free cash flow generation ($93.9M), supporting sustainable operations. However, extremely thin margins (6.6% net, 8.2% gross) and poor capital returns (ROE 2.3%, ROA 1.7%) coupled with disproportionate earnings growth (291.6% vs 16.4% revenue growth) raise quality-of-earnings concerns, suggesting non-operational gains or accounting benefits rather than fundamental operational improvement.
Repligen is growing double-digits (+16.4% YoY) with a sharp rebound in profitability and solid free cash flow (12.7% margin), backed by strong liquidity. However, very low gross margin (8.2%), muted returns (ROE 2.3%), and thin interest coverage (2.4x) point to weak earnings quality. A neutral stance is warranted until margins recover and interest coverage improves.
Why Buy Repligen Corp. Stock? RGEN Key Strengths
- Solid revenue growth of 16.4% YoY demonstrates market demand
- Exceptional free cash flow generation at $93.9M with 12.7% FCF margin provides financial flexibility
- Fortress balance sheet with 8.37x current ratio, 0.26x debt-to-equity, and $566M cash position ensures financial stability
- Positive cash conversion with operating cash flow of $117.4M supporting dividend potential and reinvestment
- Robust liquidity (current 8.37x, quick 7.12x) with $566M cash
- Healthy free cash flow ($93.9M; 12.7% margin)
- Revenue growth +16.4% YoY with significant net income rebound
RGEN Stock Risks: Repligen Corp. Investment Risks
- Critically low margins (6.6% net, 8.2% gross) indicate intense competitive pressure or unfavorable product mix typical of commoditized biologics
- Earnings growth (291.6%) vastly exceeds revenue growth (16.4%), suggesting reliance on one-time gains or tax benefits rather than sustainable operations
- Weak capital efficiency with ROE of 2.3% and ROA of 1.7% indicates capital deployment problems despite profitability
- Interest coverage of 2.4x provides limited debt service cushion; any earnings decline could strain liquidity
- Very low gross margin (8.2%) indicates pricing/COGS pressure
- Low ROE (2.3%) and ROA (1.7%) suggest inefficient capital use
- Interest coverage of 2.4x leaves limited cushion if earnings soften
Key Metrics to Watch
- Gross margin trend—must demonstrate stabilization or expansion to validate operational health
- Year-over-year revenue growth sustainability—confirm 16.4% growth is repeatable
- Return on equity and asset trends—watch for improvement toward industry-standard 8-12% ROE
- Operating cash flow consistency—ensure FCF generation is not dependent on working capital fluctuations
- Interest coverage ratio—monitor for deterioration that could constrain strategic flexibility
- Gross margin %
- Interest coverage
Repligen Corp. (RGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.37x current ratio provides a solid financial cushion.
RGEN Profit Margin, ROE & Profitability Analysis
RGEN vs Healthcare Sector: How Repligen Corp. Compares
How Repligen Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Repligen Corp. Stock Overvalued? RGEN Valuation Analysis 2026
Based on fundamental analysis, Repligen Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Repligen Corp. Balance Sheet: RGEN Debt, Cash & Liquidity
RGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Repligen Corp.'s revenue has grown significantly by 10% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.63 reflects profitable operations.
RGEN Revenue Growth, EPS Growth & YoY Performance
RGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $154.9M | -$654.0K | $-0.01 |
| Q2 2025 | $158.8M | $5.7M | $0.10 |
| Q1 2025 | $153.2M | $3.3M | $0.06 |
| Q3 2024 | $141.2M | -$654.0K | $-0.01 |
| Q2 2024 | $154.1M | $3.3M | $0.06 |
| Q1 2024 | $151.3M | $2.1M | $0.04 |
| Q3 2023 | $141.2M | $18.2M | $0.32 |
| Q2 2023 | $159.2M | $20.1M | $0.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Repligen Corp. Dividends, Buybacks & Capital Allocation
RGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Repligen Corp. (CIK: 0000730272)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGEN
What is the AI rating for RGEN?
Repligen Corp. (RGEN) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 65% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGEN's key strengths?
Claude: Solid revenue growth of 16.4% YoY demonstrates market demand. Exceptional free cash flow generation at $93.9M with 12.7% FCF margin provides financial flexibility. ChatGPT: Robust liquidity (current 8.37x, quick 7.12x) with $566M cash. Healthy free cash flow ($93.9M; 12.7% margin).
What are the risks of investing in RGEN?
Claude: Critically low margins (6.6% net, 8.2% gross) indicate intense competitive pressure or unfavorable product mix typical of commoditized biologics. Earnings growth (291.6%) vastly exceeds revenue growth (16.4%), suggesting reliance on one-time gains or tax benefits rather than sustainable operations. ChatGPT: Very low gross margin (8.2%) indicates pricing/COGS pressure. Low ROE (2.3%) and ROA (1.7%) suggest inefficient capital use.
What is RGEN's revenue and growth?
Repligen Corp. reported revenue of $738.3M.
Does RGEN pay dividends?
Repligen Corp. does not currently pay dividends.
Where can I find RGEN SEC filings?
Official SEC filings for Repligen Corp. (CIK: 0000730272) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGEN's EPS?
Repligen Corp. has a diluted EPS of $0.86.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RGEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Repligen Corp. has a HOLD rating with 65% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RGEN stock overvalued or undervalued?
Valuation metrics for RGEN: ROE of 2.3% (sector avg: 15%), net margin of 6.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RGEN stock in 2026?
Our dual AI analysis gives Repligen Corp. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGEN's free cash flow?
Repligen Corp.'s operating cash flow is $117.4M, with capital expenditures of $23.5M. FCF margin is 12.7%.
How does RGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 6.6% (avg: 12%), ROE 2.3% (avg: 15%), current ratio 8.37 (avg: 2).